Trial Profile
A Phase III, Multicenter, Randomized, Double-blind, Unbalanced (3:1) Active Control Study to Assess the Safety and Describe the Efficacy of Netupitant and Palonosetron for the Prevention of Chemotherapy-induced Nausea and Vomiting in Repeated Chemotherapy Cycles
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Nov 2019
Price :
$35
*
At a glance
- Drugs Netupitant/palonosetron (Primary) ; Aprepitant; Dexamethasone; Palonosetron
- Indications Chemotherapy-induced nausea and vomiting
- Focus Adverse reactions; Registrational
- Sponsors Helsinn Healthcare SA
- 02 Jun 2015 Results of post hoc analysis presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2015 According to Helsinn media release, the European Commission has approved netupitant/palonestron [AKYNZEO] for the prevention of acute and delayed nausea and vomiting associated with cancer chemotherapy.
- 14 May 2015 According to an Eisai Pharmaceuticals media release, results of this trial will be presented at the 51st Annual Meeting of the American Society of Clinical Oncology.